c-Met Kinase Assay Kit

Catalog #
79559
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The c-Met Kinase Assay Kit is designed to measure c-Met kinase activity for screening and profiling applications using Kinase-Glo® MAX as a detection reagent. The recombinant protein used in the kit corresponds to amino acids 956-1390 of c-Met, containing the tyrosine kinase domain.

Need us to run inhibitor screens or profile your compounds against c-Met? Check out our Kinase Screening Services.

This product has been cited 2 times.

Synonyms
Hepatocyte growth factor receptor, HGF receptor, HGF/SF receptor, Proto-oncogene c-Met, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met, MET
Product Info
Storage and Usage
Citations2
Assay Kit Format
Luminescent
Supplied As
The assay kit comes in a convenient 96-well format, with enough purified recombinant c-Met kinase, kinase substrate, ATP and kinase assay buffer for 100 enzyme reactions.
Materials Required But Not Supplied

Kinase-Glo MAX (Promega #V6071)
DTT (Dithiothreitol), 1M, optional
Microplate reader capable of reading luminescence
Adjustable micropipettor and sterile tips
30°C incubator

Format

Catalog
Number


Reagent


Amount


Storage

40255

c-Met, GST-tag*

2.5 µg

-80°C




Avoid multiple freeze/ thaw cycles!

79334

5x Kinase assay buffer

1.5 ml

-20°C

79686

ATP (500 µM)

100 µl

-20°C

40217

PTK substrate, Poly (Glu:Tyr, 4:1) (10 mg/ml)

100 µl

-20°C

79696

96-well plate, white

1

Room Temp.

 

*The concentration of the protein is lot-specific and will be indicated on the tube

UniProt #
P08581
Background

c-Met, also known as HGFR (hepatocyte growth factor receptor), is a tyrosine kinase receptor encoded by the gene MET. Upon binding its ligand HGF (hepatocyte growth factor), c-Met activates multiple cellular processes including proliferation, adhesion and angiogenesis. Importantly, c-Met is overexpressed in various carcinomas, suggesting that HGF/c-Met signaling pathway could be a promising target for cancer treatment. 

References

Recondo G. et al. Targeting MET Dysregulation in Cancer. Cancer Discov. 2020; 10(7): 922-934. Review.